Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
NeuroOne Medical Technologies ( (NMTC) ) has shared an announcement.
On May 22, 2026, NeuroOne Medical Technologies said it would amend and restate its financial statements for the quarter ended March 31, 2026, after discovering a revenue-recognition error tied to a customer order modification at quarter-end. The restatement will reduce previously reported quarterly revenue by about $0.5 million, cut gross profit by roughly $0.3 million, and increase operating and net loss by approximately $0.3 million, and the company has warned investors not to rely on its earlier Form 10-Q and related disclosures while it strengthens internal controls and prepares an amended filing.
Management stressed that the issue is confined to this one quarter, with no impact on prior periods, cash position as of March 31, 2026, or ongoing operations and growth plans. NeuroOne reaffirmed its fiscal 2026 product revenue guidance of at least $10.5 million, signaling that the correction is not expected to alter its broader business trajectory or near-term commercial outlook.
The most recent analyst rating on (NMTC) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on NeuroOne Medical Technologies stock, see the NMTC Stock Forecast page.
Spark’s Take on NMTC Stock
According to Spark, TipRanks’ AI Analyst, NMTC is a Neutral.
The score is held down primarily by persistent losses and substantial cash burn despite improving revenue and solid gross margins. Technicals are also weak with the stock trading below major moving averages and negative MACD. Offsetting factors include very low leverage and positive operational updates/guidance from the earnings call, but near-term liquidity pressure and timing-dependent catalysts limit upside confidence.
To see Spark’s full report on NMTC stock, click here.
More about NeuroOne Medical Technologies
NeuroOne Medical Technologies is a U.S. medical technology company focused on improving surgical care for patients with neurological disorders. It markets a minimally invasive, high-definition electrode platform with four FDA-cleared product families for cortical and sEEG monitoring and RF ablation of brain and trigeminal nerve targets, and is developing additional neuromodulation and drug-delivery applications.
Average Trading Volume: 38,512
Technical Sentiment Signal: Strong Sell
Current Market Cap: $35.26M
For an in-depth examination of NMTC stock, go to TipRanks’ Overview page.